Drug-eluting stent market strength
This article was originally published in The Gray Sheet
Executive Summary
Boston Scientific reports that "recent market feedback tells us that there is no significant shift in drug-eluting stent usage" due to a June 22 Wall Street Journal article raising concerns about elevated late stent thrombosis rates (1"The Gray Sheet" June 26, 2006, In Brief). The article suggested that some major hospitals are shifting back to bare metal stents for some patients. "The concerns raised last week are neither new nor have they changed nor are they measurably impacting the marketplace," CEO Jim Tobin says. The exec conceded that while there is concern over elevated stent thrombosis rates, its occurrence may be related in part to DES use in "complex diabetic patients"...